The determination of acute toxicity parameters of “Imkar-120”

A. A. Fotina, V. Levytska
{"title":"The determination of acute toxicity parameters of “Imkar-120”","authors":"A. A. Fotina, V. Levytska","doi":"10.32718/NVLVET9302","DOIUrl":null,"url":null,"abstract":"Vector-Borne Diseases are a variety of infectious and invasive diseases of animals and humans, the agents of which extend from one to another susceptible subject with the participation of hemopoiesis (ticks, insects, etc.). For the purpose of treatment of blood parasitic transmissive diseases, domestic and foreign researchers tested a significant number of drugs of different chemical composition. In connection with the insufficient on the domestic market of drugs on the basis of imidokarb dipropionate for the treatment of blood-parasitic diseases in animals, the Scientific-Production-Technical Enterprise “Brovapharma” established and conducted the state registration of the drug “Imcar-120”, which blocks the synthesis of polyamine; it also has significantly less toxicity than dimeters of aceturates. It provides a broad spectrum of antiprotozoal effects on pathogens of pyroplasmiosis of the genus Babesia (Babesia bovis, B. ovis, B. bigemina, B. colchica, B. equi, B. divergens, B. canis, B. caballi, B. gibsonii i Francaiella colchica); Teilerian species (Theileria annulata, T. sergenti, T. mutans, T. orientalis, T. ovis, T. recondita, T. tarandirangiferis); Nuttallia equi and the genus of Anaplasma (Anaplasma marginale, A. ovis, Ehrlichia canis) with their mono- or mixed infestation. Pre-clinical research “Determination of toxicological properties of the drug Imcar-120” was carried out on the basis of vivarium of the Faculty of Veterinary Medicine of Sumy NAU. Study of parameters of acute toxicity of the study drug was performed on 50 clinically healthy white mice in males and females. Before the experiment, the individual weight of the body of animals selected for the experiment was 18–22 g, the age was 8–9 weeks. In the first stage, preliminary experimental studies were conducted to determine the variation of dose limits before the main stage of the studies. At the same time the drug was administered intragastrically in doses: 2500, 3500, 4500, 5500, 6500, 7500 mg/kg. Each dose was given to three animals. After the introduction of the drug for monitoring animals, the experiment was carried out 14 days, the first day – every hour. For the expanded stage of the experiment, four experimental groups (n = 8) of animal analogues were formed, in which the study drug was injected under the same conditions as in the previous stage of the experiment at a rate of 3800, 4300, 4800 and 5300 mg/kg of body weight.  In the course of studies to determine the parameters of acute toxicity of the drug Imkar-120 it was determined half-lettable dose of the drug. According to R. Kerber's method, DL50 was 4456.25 mg/kg, therefore according to the classification of GOST 12.1.007-76 the preparation Imkar-120 should be classified as hazard class III by injection into the stomach – substances are moderately dangerous.","PeriodicalId":21677,"journal":{"name":"Scientific Messenger of LNU of Veterinary Medicine and Biotechnology","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientific Messenger of LNU of Veterinary Medicine and Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32718/NVLVET9302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Vector-Borne Diseases are a variety of infectious and invasive diseases of animals and humans, the agents of which extend from one to another susceptible subject with the participation of hemopoiesis (ticks, insects, etc.). For the purpose of treatment of blood parasitic transmissive diseases, domestic and foreign researchers tested a significant number of drugs of different chemical composition. In connection with the insufficient on the domestic market of drugs on the basis of imidokarb dipropionate for the treatment of blood-parasitic diseases in animals, the Scientific-Production-Technical Enterprise “Brovapharma” established and conducted the state registration of the drug “Imcar-120”, which blocks the synthesis of polyamine; it also has significantly less toxicity than dimeters of aceturates. It provides a broad spectrum of antiprotozoal effects on pathogens of pyroplasmiosis of the genus Babesia (Babesia bovis, B. ovis, B. bigemina, B. colchica, B. equi, B. divergens, B. canis, B. caballi, B. gibsonii i Francaiella colchica); Teilerian species (Theileria annulata, T. sergenti, T. mutans, T. orientalis, T. ovis, T. recondita, T. tarandirangiferis); Nuttallia equi and the genus of Anaplasma (Anaplasma marginale, A. ovis, Ehrlichia canis) with their mono- or mixed infestation. Pre-clinical research “Determination of toxicological properties of the drug Imcar-120” was carried out on the basis of vivarium of the Faculty of Veterinary Medicine of Sumy NAU. Study of parameters of acute toxicity of the study drug was performed on 50 clinically healthy white mice in males and females. Before the experiment, the individual weight of the body of animals selected for the experiment was 18–22 g, the age was 8–9 weeks. In the first stage, preliminary experimental studies were conducted to determine the variation of dose limits before the main stage of the studies. At the same time the drug was administered intragastrically in doses: 2500, 3500, 4500, 5500, 6500, 7500 mg/kg. Each dose was given to three animals. After the introduction of the drug for monitoring animals, the experiment was carried out 14 days, the first day – every hour. For the expanded stage of the experiment, four experimental groups (n = 8) of animal analogues were formed, in which the study drug was injected under the same conditions as in the previous stage of the experiment at a rate of 3800, 4300, 4800 and 5300 mg/kg of body weight.  In the course of studies to determine the parameters of acute toxicity of the drug Imkar-120 it was determined half-lettable dose of the drug. According to R. Kerber's method, DL50 was 4456.25 mg/kg, therefore according to the classification of GOST 12.1.007-76 the preparation Imkar-120 should be classified as hazard class III by injection into the stomach – substances are moderately dangerous.
“Imkar-120”急性毒性参数的测定
媒介传播疾病是动物和人类的各种传染性和侵袭性疾病,其病原体通过造血(蜱虫、昆虫等)的参与从一个易感主体扩展到另一个易感主体。为了治疗血液寄生虫传播疾病,国内外研究者测试了大量不同化学成分的药物。针对国内市场上以二丙酸咪唑威为基础的治疗动物血液寄生虫病的药物不足,“Brovapharma”科技生产技术企业建立并进行了阻断多胺合成的药物“Imcar-120”的国家注册;它的毒性也比乙酸酯的直径小得多。它对巴贝斯虫属(牛巴贝斯虫、羊巴贝斯虫、双头巴贝斯虫、秋赤杆菌、马巴贝斯虫、发散巴贝斯虫、犬巴贝斯虫、卡巴利巴贝斯虫、法国秋赤杆菌)热plasmiosis的病原体具有广谱的抗原性作用;盲肠菌种(环纹盲肠菌、sergenti盲肠菌、mutans盲肠菌、orientalis盲肠菌、ovis盲肠菌、recondita盲肠菌、tarandirangiferis盲肠菌);Nuttallia equi和无原体属(边缘无原体,山羊无原体,犬埃利希体)及其单一或混合侵染。临床前研究“Imcar-120药物毒理学性质的测定”以苏梅兽医学院的动物实验为基础进行。对临床健康的雄性和雌性小白鼠各50只进行了研究药物急性毒性参数的研究。试验前,所选试验动物体重18-22 g,年龄8-9周龄。在第一阶段,进行初步的实验研究,以确定剂量限值的变化,然后再进行主要阶段的研究。同时给药剂量:2500、3500、4500、5500、6500、7500 mg/kg。每种剂量给三只动物。给药后监测动物,实验进行14天,第一天-每小时。在实验扩大阶段,将动物类似物组成4个试验组(n = 8),在与前一阶段实验相同的条件下,分别以3800、4300、4800、5300 mg/kg体重的剂量注射研究药物。在确定药物Imkar-120的急性毒性参数的研究过程中,确定了药物的半可溶剂量。根据R. Kerber的方法,DL50为4456.25 mg/kg,因此根据GOST 12.1.007-76的分类,Imkar-120制剂应被归为III类胃内注射危险物质-中等危险物质。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信